Cartesian Therapeutics (RNAC) Assets (2016 - 2025)
Historic Assets for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $372.7 million.
- Cartesian Therapeutics' Assets fell 1815.03% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.7 million, marking a year-over-year decrease of 1815.03%. This contributed to the annual value of $435.0 million for FY2024, which is 4260.71% up from last year.
- Cartesian Therapeutics' Assets amounted to $372.7 million in Q3 2025, which was down 1815.03% from $388.9 million recorded in Q2 2025.
- Cartesian Therapeutics' Assets' 5-year high stood at $455.3 million during Q3 2024, with a 5-year trough of $106.0 million in Q3 2023.
- Moreover, its 5-year median value for Assets was $180.5 million (2021), whereas its average is $252.8 million.
- As far as peak fluctuations go, Cartesian Therapeutics' Assets crashed by 4051.89% in 2023, and later surged by 32940.57% in 2024.
- Cartesian Therapeutics' Assets (Quarter) stood at $159.9 million in 2021, then rose by 3.75% to $165.9 million in 2022, then surged by 83.89% to $305.0 million in 2023, then skyrocketed by 42.61% to $435.0 million in 2024, then decreased by 14.33% to $372.7 million in 2025.
- Its last three reported values are $372.7 million in Q3 2025, $388.9 million for Q2 2025, and $409.1 million during Q1 2025.